In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera

BACKGROUND: An important limiting factor in the development of centrally acting pharmaceuticals is the blood-brain barrier (BBB). Transport of therapeutic peptides through this highly protective physiological barrier remains a challenge for peptide drug delivery into the central nervous system (CNS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillemyn, Karel, Kleczkowska, Patrycja, Novoa, Alexandre, Vandormael, Bart, Van den Eynde, Isabelle, Kosson, Piotr, Asim, Muhammad Faheem, Schiller, Peter W, Spetea, Mariana, Lipkowski, Andrzej W, Tourwé, Dirk, Ballet, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284447/
https://www.ncbi.nlm.nih.gov/pubmed/22289619
http://dx.doi.org/10.1186/1756-6606-5-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3284447/
https://www.ncbi.nlm.nih.gov/pubmed/22289619
http://dx.doi.org/10.1186/1756-6606-5-4

Ejemplares similares